1. Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade
- Author
-
Xi Wu, Ya Luo, Yanlin Feng, Xin Bai, Yan Fu, Hubing Shi, Ying Shi, Yu Bao, Changyang Gong, Jie Xu, Jianping Hu, Li Chai, Bo Chen, Rongjie Zhang, Yan Wang, Xiaowei Liu, Huifang Li, Jinen Song, Haiyuan Zhang, Yongzhang Luo, and Jiqiao Yang
- Subjects
Photothermal Therapy ,medicine.medical_treatment ,Pharmaceutical Science ,02 engineering and technology ,Targeted therapy ,03 medical and health sciences ,Immune system ,Cell Line, Tumor ,Tumor Microenvironment ,Medicine ,Humans ,Immune Checkpoint Inhibitors ,030304 developmental biology ,0303 health sciences ,Tumor microenvironment ,business.industry ,Melanoma ,021001 nanoscience & nanotechnology ,medicine.disease ,Immune checkpoint ,Blockade ,Regimen ,Cancer research ,Immunogenic cell death ,Gold ,0210 nano-technology ,business - Abstract
The combination of MAPK-targeted therapy and immune checkpoint blockade is one of the most promising regimens for patients with advanced melanoma. However, the synergistic efficacy of the combo regimen is still controversial in clinical trials. Here, we report that MAPK inhibition induced T-cell suppression within tumor microenvironment is mediated by attenuation of HSP27/HSP70 and deficiency of neoantigen presentation. To address this problem, we designed a photothermal-responsive on-demand controlled drug release gold nano-system to carry BRAF inhibitor. The nano-system can be specifically delivered into tumor cells rather than T-cells, and effectively transformed the optical energy into heat energy upon laser irradiation. Combination of photothermal and targeted therapy significantly promoted immunogenic cell death and T-cell infiltration. On top of this regimen, systematically administration of PD-1 antibody not only suppressed local-treated tumor but also inhibited abscopal tumor by enhancing generalized immune-related antitumor response. More importantly, the triple-combo regimen could efficiently convert immune "cold" tumors into "hot" ones. In conclusion, our research proves the advantage of photothermal-targeted-immune triple combinatorial regimen in treating tumors which are clinical unresectable multifocal and lack of T-cell infiltration.
- Published
- 2020